Breaking News

Hospira One 2 One To Supply Solithromycin

Cempra to develop IV version of antibiotic

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cempra Pharmaceuticals has entered into an agreement with Hospira One 2 One to develop an intravenous form of its lead antibiotic candidate, solithromycin. Hospira One 2 One will supply the IV version of the antibiotic for clinical development and potential commercial supply. Financial terms were not disclosed. This story was first reported by Triangle Business Journal Online.   If the drug reaches approval, Cempra will purchase at least 80% of its commercial product from Hospira, according to a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters